Tumor Necrosis Factor Receptor Superfamily Member 18 ? Pipeline Review, H1?2018Posted by Vansh Rao on February 7th, 2018 Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Tumor Necrosis Factor Receptor Superfamily Member 18 Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated Tlymphocytes and endothelial cells and in the regulation of Tcell receptormediated cell death. It mediated NFkappaB activation via the TRAF2/NIK pathway. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 4 and 2 respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, NonSmall Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Blood Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lymphoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma and Transitional Cell Carcinoma Urothelial Cell Carcinoma. Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Scope The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18
For more information, please visit @ https://www.24marketreports.com/life-sciences/tumor-necrosis-factor-receptor-superfamily-member-18-glucocorticoid-induced-tumor-necrosis-factor-receptor-or-activation-inducible-tnfr-family-receptor-or-glucocorticoid-induced-tnfr-related-protein-or-cd357-or-tnfrsf18pipeline-review-h1-2018-market-67 Table Of Content- List of Tables 4 Contact Us- New York City Zone 01,
Like it? Share it! More by this author |